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in the central nervous system following
ischemic injury
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Abstract
Background: Ischemic stroke induces neuronal death in the core of the infarct within a few hours and the
secondary damage in the surrounding regions over a long period of time. Reduction of inflammation using
pharmacological reagents has become a target of research for the treatment of stroke. Cyclooxygenase 2 (COX-2), a
marker of inflammation, is induced during stroke and enhances inflammatory reactions through the release of
enzymatic products, such as prostaglandin (PG) E2.
Methods: Wild-type (WT) and COX-2 knockout (COX-2KO) mice were subjected to middle cerebral artery occlusion
(MCAO). Additionally, brain slices derived from these mice or brain microvascular endothelial cells (BMECs) were
exposed to oxygen-glucose deprivation (OGD) conditions. The expression levels of extracellular matrix (ECM)
proteins were assessed and correlated with the state of inflammation.
Results: We found that components of the ECM, and specifically laminin, are transiently highly upregulated on
endothelial cells after MCAO or OGD. This upregulation is not observed in COX-2KO mice or WT mice treated with
COX-2 inhibitor, celecoxib, suggesting that COX-2 is associated with changes in the levels of laminins.
Conclusions: Taken together, we report that transient ECM remodeling takes place early after stroke and suggest
that this increase in ECM protein expression may constitute an effort to revascularize and oxygenate the tissue.
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Background
Cerebral ischemia results in neurological disability and
constitutes the third leading cause of death in the US.
It has devastating consequences as it results in death
of neurons at the infarct core within a few hours after
the blockade of blood flow to the brain [1]. Although
re-establishment of blood flow using fibrinolytics is crit-
ical, inflammation that develops following the initial
ischemic episode is a major mechanism by which cells in
the penumbra degenerate [2], and therefore pharmaco-
logical strategies are formulated to limit this delayed phase
of damage. Major mediators of inflammatory events are
the members of the cyclooxygenase (COX) family. The
two major COX isoforms are COX-1 and COX-2 and they
catalyze the first step in the transformation of arachidonic
acid to prostaglandins (PGs) and thromboxanes. In the
central nervous system (CNS), COX-1 and COX-2 are
expressed constitutively on neurons, whereas COX-2 is
induced on microglia and astrocytes by inflammatory
stimuli or injury [3,4]. COX-2 is considered a proinflam-
matory mediator leading to PG synthesis [5]. Prostaglan-
din E2 (PGE2) induces fever and pain, increases vascular
permeability and recruit inflammatory cells to injury sites
[6]. However, evidence suggests that COX-2 is also
involved in inflammation reduction/resolution [7,8]. The
COX-2 inhibitors NS398 and indomethacin have differ-
ential effects depending on their administration time:
early administration during a pleurisy model suppressed
inflammation, but late administration exacerbated inflam-
mation through PGE2 and 15-deoxy-δ12,14-prostaglandin
J2 (15d-PGJ2) [7]. In a different paradigm, PGE2 reduced
proinflammatory mediators release from mast cells and
inflammatory cells recruitment in lungs [9], suppressed
inducible nitric oxide synthase (iNOS) and tumor nec-
rosis factor (TNF)α, but enhanced interleukin 10 and
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interleukin 13 expression in LPS-stimulated microglia
[10,11]. COX-2 also oxygenates anti-inflammatory endo-
cannaboids [12] that protect against ischemic death [13].
These studies suggest that COX-2 can drive or resolve in-
flammation; therefore, careful regulation of COX-2 may
be important for reducing inflammation-mediated neuro-
degeneration [14,15].
The extracellular matrix (ECM) of the CNS is essential
for maintenance of brain homeostasis. Although its
exact composition is not defined, it is thought that hya-
luronan, tenascin-C, and proteoglycans are present in
brain parenchyma [16], and fibronectin (FN) and lam-
inin in the brain vasculature [17,18]. Proteoglycans such
as aggrecan, versican, and brevican constitute perineuro-
nal nets majorly [19,20], and tenascin is involved in
regulation or promotion of neurite outgrowth [21-23].
Moreover, the structure of these molecules is changed in
response to brain injury such as stroke [24,25]. The
ECM and secreted neurotrophic or other factors, such
as vascular endothelial growth factor (VEGF) or brain-
derived neurotropic factor (BDNF), are involved in neur-
onal reorganization and recovery in MCAO brains
[24,26-31]. Among the ECM proteins, laminin is rich
primarily in the basement membranes of the endothelial
cells of the blood–brain barrier (BBB) [32]. Laminin
levels have been reported to increase or decrease during
CNS injury [29,33]. Laminins are present in 16 isoforms
that are composed of α, β and γ polypeptides. Different
laminin isoforms have unique distribution, and are tem-
porally and spatially regulated [34]. Several of the lam-
inin subunits have been shown to be expressed in the
rodent brain, including α1 to 5, β1, and γ1 [35,36], and
the β3 and γ1 chains have been reported in sprouting
neurons and rat astrocytes [37,38]. Laminin α2 is loca-
lized in the basal lamina of cerebral blood vessels, and
may be important for the selective filtration capability of
BBB [39]. The expression of laminin is upregulated in
endothelial cells and astrocytes within 24 h following is-
chemia and stab wounds [40,41].
The work described here investigated whether COX-2
can modulate ECM changes induced by ischemic injury.
We focused on laminin as one abundant component of
the ECM. Our results indicate that laminin levels on
blood vessels are regulated by COX-2 following perman-
ent or transient ischemia. Understanding the functional
outcome and timing of laminin expression regulation by
COX-2 in the progression of ischemia-induced neuronal
damage could suggest a basis for potentially rationalizing
drug specific interference with ischemia.
Methods
Animals and in vivo experiments
All animal procedures were approved by the Stony Brook
University Institutional Animal Care and Use Committee
(IACUC). Adult wild-type (C57BL6; WT) mice were
obtained from Jackson Laboratory (Bar Harbor, ME,
USA). Cyclooxygenase knockout mice (COX-2KO in the
C57Bl6 background) were provided by Dr SK Dey (Cin-
cinnati Children's Hospital). Mice were bred in house
at Stony Brook. For middle cerebral artery occlusion
(MCAO), mice were anesthetized and underwent perman-
ent MCAO (pMCAO) using a heat-blunted, small 6–0
siliconized monofilament (Ethicon, Somerville, NJ, USA).
A fiberoptic probe was glued to the parietal bone (2 mm
posterior and 5 mm lateral to bregma) and connected to a
laser-Doppler flowmeter (Periflux System 5010, Perimed,
Stockholm, Sweden) for continuous monitoring of cerebral
blood flow in the ischemic territory center. Celecoxib (Bio-
vision, Milpitas, CA, USA) was given at 5 mg/kg intraperi-
toneally (in 50 % dimethylsulfoxide (DMSO)) 30 minutes
before the injury. The animals were killed at different
times. The infarct area was visualized by cresyl violet and
2,3,5-triphenyltetrazolium chloride (TTC) staining.
Tissue preparation
Mice were anesthetized after surgery and perfused with
saline solution, followed by 4 % paraformaldehyde (PFA)
in 0.1 M phosphate buffer, pH 7.2, for tissue fixation.
Brains were obtained and post fixed overnight at 4 °C
in 4 % PFA. Fixed brains were stored at 4 °C in 30 %
sucrose solution until they sank. Six separate series of
20 μm coronal brain sections were obtained with a cryo-
stat. For protein preparation, mice were anesthetized
and perfused with saline. Brains were sliced with Mice
Brain Slicer Matrix (ASI Instruments, Warren, MI, USA)
and a razor blade. The slice including the ipsilateral
sides (ischemic lesion) was selected, and tissue blocks
(1.0 × 1.0 × 1.0 mm3) in the lesion of ipsilateral sides and
in the same area of contralateral (not ischemic) sides
were collected, and stored at −70 °C until use.
Measurement of Infarct volume
To quantify the infarct volume TTC staining was used:
mice were killed and perfused with saline after MCAO.
The brain slices, obtained as described above, (2 mm)
were incubated for 15 minutes in 2 % TTC (Sigma-
Aldrich, St. Louis, MO, USA) at 37 °C, and fixed in 4 %
PFA at 4 °C. TTC stains viable brain tissue dark red,
whereas infarcted tissue areas remain unstained (white).
To measure the TTC-negative area, serial sections from
each animal were viewed in a Nikon E600 microscope,
photographed and the area measured using NIS-
Elements software (ImageJ). The infarct volume was calcu-
lated as sum of (area × section thickness) for each animal.
Oxygen-glucose deprivation (OGD)
Immortalized human brain microvascular endothelial
cells (BMECs) were a gift from Dr M Stins at Johns
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Hopkins University, School of Medicine [42]. BMECs
were cultured in RPMI1640 medium, supplemented with
10 % NuSerum, 10 % fetal bovine serum (FBS), minimal
essential medium (MEM) vitamins, MEM non-essential
amino acids, 1 mM sodium pyruvate, 2 mM D-glutamine,
30 μg/ml endothelial growth supplement, 5 U/ml heparin,
and penicillin/streptomycin at 37 °C in 5 % CO2. The
cells form a monolayer connected via tight junctions that
can form and model an in vitro blood–brain barrier [43].
For in vitro ischemia, the cells were maintained in
glucose-free and serum-free (OGD conditioned) medium
under 1 % O2/5 % CO2 at 37 °C (Oxycycler C4, Bio-
spherix, Redfield, NY, USA) for 3 days. Afterwards,
the cells were removed from the hypoxic chamber and
replaced with pre-OGD conditioned medium in a humi-
dified aerobic incubator at 37 °C for 4 h recovery [44].
Immunoblotting, immunohistochemistry,
and immunofluorescence
For immunoblotting, cells or tissue from the ipsilateral
or contralateral hemisphere were lysed in 50 mM Tris–
HCl (pH 7.4) containing 1 % Nonidet P-40, 0.25 % Na-
deoxycholate, 150 mM NaCl, and protease inhibitors
cocktail (Sigma-Aldrich) using a homogenizer on ice,
incubated for 30 minutes, and centrifuged. The extracts
were run on a reducing 10 % sodium dodecylsulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to polyvinylidene fluoride (PVDF) membrane
(Immobilon-P; Millipore, Billerica, MA, USA). The blots
were incubated using primary antibodies (Table 1) over-
night at 4 °C; followed by incubation with horseradish
peroxidase-labeled secondary antibody (Invitrogen,
Carlsbad, CA, USA) for 1 h at room temperature, and
enhanced chemiluminescence (ECL) (Pierce Chemical
Co., Rockford, IL, USA). After stripping, the membranes
were reblotted with mouse anti-α-tubulin (Upstate Bio-
technology, Lake Placid, NY, USA) antibody. Expression
levels were quantified using the ImageJ software, normal-
ized against α-tubulin. For immunohistochemistry and
immunofluorescence, sections were fixed in 4 % PFA in
phosphate-buffered saline (PBS) for 30 minutes. After
washing in PBS, they were blocked in 0.2 % Triton X-100
and 1 % bovine serum albumin (BSA) in PBS. The
primary antibodies used were listed in Table 1. The sec-
tions were incubated with primary antibody in 0.2 %
Triton X-100 and 1 % BSA in PBS at 4 °C overnight.
After rinsing in PBS, the sections were incubated with
biotinylated secondary antibodies, the avidin/biotin sys-
tem, and visualized using 3,3'-diaminobenzidine, or Alexa
Fluor488-conjugated or Alexa Fluor555-conjugated sec-
ondary antibodies (Invitrogen) for 1 h. The sections were
rinsed in PBS, coverslipped, and examined using confocal
microscopy or epifluorescence microscopy.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol (Invitrogen) and
cDNA was prepared using reverse transcriptase, accord-
ing to manufacturer’s instructions (Invitrogen). The PCR
primers used are listed in Table 2. PCR products were
separated by electrophoresis in 1 % agarose gels and
detected under ultraviolet (UV) light.
Table 1 Antibodies used for immunostaining or immunoblotting
Antigen Antibody Dilution Source Catalog no. Method
NeuN Mouse monoclonal 1:1,000 Chemicon MAB377 IHC
Iba-1 Rabbit polyclonal 1:1,000 Wako 019-19741 IHC
TLR9 Rabbit polyclonal 1:500 Imgenex IMG431 WB
CD14 Goat polyclonal 1:1,000 Santa Cruz Biotechnology sc-6999 WB
Fibrin Mouse monoclonal 1:200 A gift of Dr Galanakis [45] WB
Collagen IV Rabbit polyclonal 1:500 Chemicon AB756 WB
Pan-laminin Rabbit polyclonal 1:1,000 Sigma-Aldrich L9393 IHC
1:5,000 WB
α-Tubulin Mouse monoclonal 1:7,000 Upstate Biotechnology 05-829 WB
Occludin Mouse monoclonal 1:250 Zymed 33-1500 IHC
HIF-1α Rabbit polyclonal 1:1,000 Bethyl Laboratories A300-286A WB
COX-2 Mouse monoclonal 1:500 BD Biosciences 610203 WB
Mac-2 Rat monoclonal 1:1,000 Cedarlane CL8942AP WB
CD45 Rat monoclonal 1:500 BD Biosciences 553076 IHC
VEGF Rabbit polyclonal 1:200 Thermo scientific RB-9031 WB
GFAP Rabbit polyclonal 1:1,000 DAKO Z0334 IHC
COX-2, cyclooxygenase 2; GFAP, glial fibrillary acidic protein; HIF-1α, hypoxia-inducible factor 1α; Iba-1, ionized calcium binding adaptor molecule 1; IHC,
immunohistochemisty; TLR9, Toll-like receptor 9; VEGF, vascular endothelial growth factor; WB, western blot.
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Statistics
Statistical significance was assessed by analysis of vari-
ance (ANOVA), followed by Student-Newman-Keuls
multiple comparison tests. All analyses were performed
using SPSS, V.8.0 (SPSS, Chicago, IL, USA). Values are
means ± SEMs of at least three independent experiments
using at least five animals per experimental procedure
and mouse strain, unless otherwise indicated.
Results
Laminin expression is transiently upregulated in
wild-type, but not COX-2KO, mice after MCAO
We used permanent MCAO (pMCAO) to investigate
how ischemia-induced local inflammatory events affect
the ECM. The extent of neuronal death and local inflam-
mation (microglial cell activation) were assessed over
time. The number of Nissl bodies was reduced at 3 h
compared to that in contralateral sides following
pMCAO (Figure 1A,B and Additional file 1: Figure S1)
and the infarct volume was increased (Figure 1E).
Regions not stained with TTC indicating cerebral infarc-
tion were observed within 6 h following pMCAO
(Figure 1C). The state of microglial activation was also
visualized using the Iba-1 marker, which is specific for
macrophages/microglia (Figure 1D). Change of microglial
morphology to an ameboid state was observed using Iba-
1 staining within 1 to 3 h after pMCAO, and sustained
until at least 48 h after the injury. Similarly, the infiltra-
tion of leukocytes was assessed after MCAO (Additional
file 1: Figure S1): immunoreactivity for CD45 was evident
1 h after MCAO, as well as at later timepoints, namely at
24 and 48 h.
As COX-2 is one of the critical contributors to micro-
glial activation [4], we assessed the extent of neuronal
death and other parameters in COX-2−/− mice (COX-
2KO) relative to wild-type (WT) animals. COX-2KO
mice were subjected to MCAO alongside WT animals.
At 12 h after injury the extent of neurodegeneration in
COX-2KO mice was decreased compared to WT mice
(Figure 2A, upper and infarct volume graph), as reported
previously [46]. Microglial activation was similarly
reduced (data not shown). When we evaluated the
expression of common ECM components, we found that
proteins such as laminin, fibrinogen, fibronectin (not
shown), and collagen IV were upregulated in ischemic
brain (Figure 2B,C). The markers tested exhibited a
transient increase after MCAO in WT animals. This
transient increase was not detectable in the sham
and contralateral (not ischemic) side, marked in Figure 2B,
C as C12 (contralateral side 12 h post MCAO). In COX-
2KO tissue extracts, the transient increase was not
observed at the time points examined. This result sug-
gests that the MCAO injury probably induces and COX-
2 could be involved in an inflammation-mediated change
in the ECM protein expression.
Since laminin was the ECM protein whose levels were
predominantly affected by MCAO, and given the known
involvement of laminin in revascularization, we exam-
ined whether the MCAO and ECM changes also involved
changes in the expression of VEGF, a factor known for
mediating angiogenesis and neoangiogenesis. As shown
in Additional file 2: Figure S2, the levels of VEGF were
elevated in wild-type animals at 6 and 12 h post MCAO
(peak at 6 h), but this increase was drastically attenuated
in COX-2KO mice, suggesting that COX-2 could be
involved in laminin-mediated angiogenesis [47].
Laminin is increased in endothelial cells after
ischemic injury
Among the ECM markers investigated, the most prom-
inent change in protein levels was observed in laminin,
as shown in Figure 2C. In the subsequent experiments
we focused our investigation on laminin and its expres-
sion after stroke. To ascertain the cellular localization of
laminin, we used occludin as an indicator of endothelial
cells on the blood vessels since laminin has been consid-
ered as a major component of the ECM of the BBB [17].
Laminin expression was prevalent on occludin+ cells
(Figure 3A), demonstrating that endothelial cells were
one cellular source of upregulated laminin [36,48]. To
further confirm that laminin expression was increased
Table 2 Primer sequences for reverse transcription
polymerase chain reaction (RT-PCR)
Gene Forward/reverse Sequences (5’-3’)
Laminin α2 F GCCGCACTCCTGGACCAACC
R TGCCAGTGCTCGCAGCCATC
Laminin α4 F ATCGAGGGGAGCGCAGTGGT
R GCAGAACCGGGGTGTGCCTC
Laminin α5 F CTGTGGAGCCCGCCTGTGTG
R CCCCACGCGACACTGGTCAC
Laminin β1 F CGAACCTGCAGCGAGTGCCA
R GTTCCGCTGCTGGGCTCTGG
Laminin β3 F CCAGCGCACACGGCTTCTCA
R GTGCCCTGCCGAAGGTTCCC
Laminin γ1 F CTGTGAGACTGTGCCGCCCG
R ACAGTGCTGGCCGGTGATGC




Using permanent MCAO we followed the effect of ischemia and local
inflammation, and using transient MCAO we followed the effect of systemic
inflammatory cell infiltration on changes in ECM proteins during post-injury
CNS reorganization.
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on endothelial cells, brain microvascular endothelial
cells (BMECs) were subjected to conditions of OGD,
as described in the Methods section, and analyzed by
immunoblotting. Laminin expression, in particular β and
γ subunits, was upregulated on endothelial cells follow-
ing injury (Figure 3B).
The antibody used in Figures 2C and 3A,B was a pan-
laminin antibody, so we sought to determine which lam-
inin subunits are upregulated after MCAO. We used
semiquantitative RT-PCR for each laminin subunit in
extracts from the ipsilateral side of MCAO animals at
the indicated times (Figure 3C). The analysis showed that
laminins α2, β3, and γ1 were upregulated within 24 h
(Figure 3C).
Pharmacological inhibitors of COX-2 modulate laminin
levels after MCAO
COX-2 deficiency modulated the levels of several ECM
markers following MCAO (Figure 2B,C). Focusing again
on laminin, we assessed whether this effect of COX-2
was acute or rather a potential developmental effect.
To address this concern, we impaired COX-2 activity
pharmacologically using celecoxib (coxib). We used first
OGD in culture, as described above. Coxib was given at
2.5 and 5 μM during the OGD and the levels of laminin
were examined using immunoblotting. As shown in
Figure 4A,B, the OGD samples had higher levels of
laminin compared to control samples. When coxib was
used, the levels of laminin were decreased down to con-
trol levels. Similar to laminin, the hypoxia inducible fac-
tor 1α (HIF-1α), which a classic marker upregulated
during ischemia or OGD [49], was decreased in the
presence of coxib. The levels of α-tubulin or COX-2
remained the same in all conditions. Coxib was also
administered in vivo to wild-type mice immediately
before MCAO. More intact Nissl bodies were observed
in coxib-treated mice (WT+ coxib) compared to control
ones that had not been treated with coxib (WT+ vehicle)
(Figure 4C). In these Nissl- area, laminin expression was
dramatically decreased in coxib-treated mice (+coxib)
compared to control mice (vehicle) (Figure 4C,D) and
was reminiscent of laminin expression levels in COX-
2KO mice. Notably, the intense staining indicating
increased expression of blood vessels (endothelial cells)
was not observed in the coxib-treated animal tissues.
These results suggest that COX-2 can regulate acutely
laminin expression.
COX-2 acts through E-prostanoid 3 (EP3) receptors
to modulate ECM protein expression
We assessed whether the effect of COX-2 on laminin
and ECM protein expression was mediated through
prostaglandins and prostaglandin receptors. We used
pharmacological inhibitors of EP receptors on BMECs
Figure 1 Neuronal death and Iba+ microglia in ischemic brain following middle cerebral artery occlusion (MCAO). Sections at the
indicated times after MCAO were stained with cresyl violet (B), 2,3,5-triphenyltetrazolium chloride (TTC) (C), and Iba-1 antibody (D). Contralateral
sides were used as controls. Upper and lower sections are from the cortex and striatum, respectively. The sections were stained with cresyl
violet; the areas of neuronal death were revealed by the absence of cresyl violet stain and are represented in the cartoons as gray shading (A).
(E) Infarct volume was measured as described in the Methods section. Data were obtained from five animals per timepoint. Values are
means ± SEMs of at least three independent experiments of each group unless otherwise indicated. Bars, 50 μm.
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and subjected them to OGD. Of the antagonists used,
SC51089 (EP1), AH6809 (EP2), L798,106 (EP3) and
AH23848 (EP4), only the EP3 antagonist decreased lam-
inin levels (Figure 5A). The combination of coxib and
L798,106 did not result in further laminin decrease
expression (Figure 5B). This result suggests that COX-2
regulates laminin expression via EP3 receptor activation,
which mainly function to inhibit adenylyl cyclase via Gi
activation [50].
As discussed earlier, in Figure 2, other ECM protein
components were also increased after MCAO, and their
expression correlated with increased inflammation. We
Figure 2 Impaired laminin expression in COX-2 knockout (COX-2KO) mice following ischemic injury. Lower magnification images of
cresyl violet staining ((A), upper) on brain sections from wild-type (WT control) and COX-2KO, mice that were subjected to middle cerebral artery
occlusion (MCAO). Sections shown were collected 12 h after MCAO and stained with cresyl violet. White dotted lines demarcate the infarct.
*P <0.05 compared to WT control or WT vehicles. (B,C) Extracellular matrix (ECM) protein expression in extracts from ipsilateral sides after MCAO
was analyzed for Toll-like receptor 9 (TLR9), CD14, fibrin(ogen), collagen IV (B), and laminin levels (α, β and γ subunits) (C) and was quantified
using the ImageJ software, normalized against α-tubulin and graphed as fold difference in mean intensity. *P <0.01 compared to the
contralateral WT and COX-2KO sides at 12 h (C12). Data were obtained from at least five animals in each group.
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evaluated the expression of markers not directly asso-
ciated with the COX-2 pathway (TLR9, Mac-2, CD14) in
the presence of coxib or EP antagonists, and found that
their expression was also decreased when the COX-2
pathway was inhibited (Figure 5C). These results sug-
gested that laminin and other ECM protein expression
increase is associated with brain inflammation.
Because the EP3 inhibitor inhibited the induction of
laminin (Figure 5A), we explored whether incubation of
BMECs with PGE2 would result in increase of laminin
expression. The cells were treated with increasing con-
centrations of PGE2 over a period of 2 days. As shown in
Figure 6, a strong upregulation of all laminin subunits was
evident at the 1-day but mostly at the 2-day timepoint.
This result further supports the involvement of COX-2
/PGE2 in the processes that lead to laminin induction.
Discussion
ECM components play regulatory roles in various cellu-
lar events [51-53], including healing/repair processes
Figure 3 Laminin expression increased on blood vessels following transient middle cerebral artery occlusion (tMCAO). (A) At 6 h post
MCAO, sections were stained with antibodies against anti-pan-laminin and occludin. Data are representative of results from at least five animals.
Scale bar, 100 μm. (B) Brain microvascular endothelial cells (BMECs) were challenged with oxygen-glucose deprivation (OGD) and assayed for
laminin expression. *P <0.01 compared to control. (C) RT-PCR for laminin subtypes at indicated times after MCAO.
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after injury [54]. For some ECM proteins it has been
reported that their expression increases in ischemia and
stab wounds [40,41], but it is not known what its contri-
bution to the injury outcome is. Focusing on one ECM
component, we report that the increase in laminin
depends on COX-2 activity.
Laminin upregulation has been linked to wound heal-
ing stimulation [54,55] and angiogenesis. In a skin
wound model, application of laminin peptides increased
the wound coverage and repair and was accompanied by
enhanced angiogenesis. Laminins α2, β3, and γ1 are
increased in brain following transient ischemic injury.
Figure 4 Impaired laminin expression in cyclooxygenase 2 (COX-2)-inhibited cells and mice following ischemic injury. (A) Brain
microvascular endothelial cells (BMECs) were treated with celecoxib (coxib, 2.5 and 5 μM) and subjected to oxygen-glucose deprivation (OGD). (B)
Laminin expression was determined in cell extracts. α-Tubulin normalized protein loading. Bands were quantified by densitometry and plotted as
mean intensity. The value of laminin expression in bar graph was averaged over all experiments for the expression of all laminin subunits;
*P <0.01. (C) Lower magnification images of cresyl violet staining (upper) of brain sections from wild-type (WT) mice treated with vehicle alone
(WT+ vehicle) and the COX-2 inhibitor coxib (WT+ coxib) prior to middle cerebral artery occlusion (MCAO). White dotted lines demarcate the
infarct. Infarct volume was measured. *P <0.05 compared to WT vehicle (lower). (D) Sections shown were collected 12 h after MCAO and stained
with pan-laminin antibodies. Data are representative of results from three independent experiments. Bars, 50 μm.
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These laminins have been reported to be expressed in
brain [33,38,56]. The biological roles of laminin subtypes
and trimer molecules are largely unknown, thus, infor-
mation about their functions derives from the phenotype
of deficient or knockout mice. Laminin α1 is involved in
epiblast differentiation [34]. Laminin α2 is expressed in
basal lamina surrounding neurons and muscle [57]. α2
deficiency causes congenital muscular dystrophy [58].
Laminin β1 deficient mice lack basement membranes
and display defects in the neuromuscular synapse [34].
Laminin β3 is expressed on the basal lamina and
ECM of all cerebral microvessels [59]. The γ1 subunit is
rapidly degraded during excitotoxicity [60] or ethanol-
induced neurodegeneration [61]. Although these subu-
nits were upregulated after MCAO, it is not clear if they
form a single laminin isoform or distinct heterotrimers.
Moreover, it is not clear if they would act through the
same receptors, integrins, dystroglycan or syndecan [34].
COX-2 activity enhances the production of VEGF [47],
which in turn stimulates angiogenesis. The downstream
effectors of COX-2 would be different prostaglandins
such as PGI2, PGD2, PGE2, PGF2α, and thromboxane
(Tx). These prostaglandins bind to the receptor with the
greatest affinity: I prostanoid (IP) receptor binds PGI2,
DP binds PGD2, EP binds PGE2, FP binds PGF2α, and
TP binds TxA2, and they are basically G protein-coupled
prostanoid receptors (GPCR) [62,63]. Among the prosta-
glandins, prostaglandin E2 (PGE2) is the most widely
produced prostaglandin in the body, and considered to
participate in inflammation associated with redness,
swelling and pain [64,65] and has significant effects on
proliferation, the apoptosis of lymphocytes and the
Figure 5 Decreased laminin expression in cyclooxygenase 2 (COX-2)-inhibited endothelial cells following oxygen-glucose deprivation
(OGD). (A) Cells were pretreated with antagonists, subjected to OGD and western blot analysis. AH, AH6809 (1 μM; Ki = 350 nM), EP2 antagonist;
L, L798,106 (1 nM; Ki = 0.3 nM), EP3 antagonist; A, AH23848 (1 μM; IC50 = 0.26 μM), EP4 antagonist. (B) Laminin expression in COX-2-inhibited
endothelial cells following OGD. Cells were pretreated with antagonists, subjected to OGD and western blot analysis. (C) Brain microvascular
endothelial cells (BMECs) were pretreated with celecoxib (coxib) and antagonists for 15 minutes, then subjected to OGD and western blot
analysis using antibodies against Toll-like receptor 9 (TLR9) and Mac-2. α-Tubulin was used to normalize protein loading. Quantification was
performed using the ImageJ software, normalized against α-tubulin. *P <0.01 compared to control. Data are representative of results from at
leas five experiments.
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regulation of cytokine production in T cells [64]. PGE2
has the most known receptors with EP subtypes charac-
terized as EP1 to EP4. Depending on the model of CNS
injury, different EP receptors mediate the cellular sig-
nals. In a model of pulmonary emphysema angiogenesis
was mediated by an EP2 agonist [66], whereas bone mar-
row cells expressing EP3 receptor enhanced angiogenesis
during chronic inflammatory conditions [67]. In Lewis
lung carcinoma the proangiogenic microenvironment
was regulated via COX-2/EP3 or EP4 signaling [56]. In
our study the effects of COX-2 on laminin expression
were mediated through EP3 receptors. Our results sug-
gest that although ECM changes are associated with the
general acute inflammatory processes after MCAO, they
may result from specific signaling changes. This latter
hypothesis is supported by the fact that not all EP
antagonists affect laminin expression, yet all affect other
marker expression.
The observation that eventually laminin expression
was recovered in COX-2-deficient animals at 2 days
(data not shown) suggests that COX-2 deficiency delays
the upregulation of the ECM protein laminin, potentially
due to the release of different prostaglandins at early
and late inflammatory stages and/or neuronal recovery
during ischemic injury.
If the initial response of the ischemic tissue is an
effort to promote neoangiogenesis to re-establish the
blood flow [68,69], our data suggest that the early
inflammatory reactions may be aiding such a process.
Our results also point to molecular components critical
for increased vascularization, suggesting that inhibition
of molecules, such as EP3, may not be beneficial for
stroke outcome.
Conclusions
Our study shows that following MCAO a transient upre-
gulation of proteins of the ECM is observed, primarily
of proteins associated with the endothelial cells of the
CNS blood vessels. The presence of COX-2 and the
pathway it initiates are important for this upregulation.
Although we do not currently know why this ECM pro-
tein changes occur, we speculate that they constitute an
early endogenous proangiogenic attempt from the tissue
to re-establish oxygenation of the surrounding tissue.
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α-Tubulin was used to normalize protein loading. *P <0.01 compared
to control.
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